Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB801 in Combination With Chemotherapy and Immunotherapy in Cholangiocarcinoma or Pancreatic Adenocarcinoma
NCT07619313Phase 1Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- May 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of ligritinib in cholangiocarcinoma (CCA) and pancreatic adenocarcinoma (PDAC) (2 cohorts), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Incidence of dose limiting toxicities at 28 days. Started May 2026; status: recruiting.
02
Drugs
ligritinib
03
Conditions
cholangiocarcinoma (CCA)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07619313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619313.